Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable
17 July 2024
Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies
17 July 2024
Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise
17 July 2024
Betsy Goodfellow from Pharmafocus considers the details of the infected blood scandal, from its beginning to the outcome of the recent inquiry
17 July 2024
Betsy Goodfellow from Pharmafocus considers Pride month and the state of LGBTQ+ healthcare in the UK
4 June 2024
Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment
28 April 2024Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable
17 July 2024Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies
17 July 2024Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise
17 July 2024
Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments
4 June 2024
Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments
4 June 2024Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment
28 April 2024
Ascendis Pharma has announced that the MHRA has granted marketing authorisation for Yorvipath (palopegteriparatide, developed as transcon pth) in Great Britain as a parathyroid hormone (pth) replacement therapy for the treatment of adult patients with chronic hypoparathyroidism.
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option for preventing chronic and episodic migraines in adults who typically have at least four migraine days per month and where three previous preventative options have failed.
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a maintenance therapy for patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) following stabilisation with an intravenous immunoglobin therapy (IVIG).
AbbVie has announced that the NICE has recommended Tepkinly (epcoritamab) as a treatment option for adults with diffuse large b-cell lymphoma (DLBCL) whose cancer has returned or not responded to two previous treatments.
The UKHSA has warned that further outbreaks of measles could spread to other towns and cities unless uptake in the measles, mumps and rubella vaccination is increased in at-risk areas.
Virocell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials.
AbbVie has announced that the MHRA has granted a marketing authorisation for Aquipta (atogepant), for the prophylaxis of migraine in adult patients who have had at least four migraine days each month.
Amicus Therapeutics has announced that the MHRA in the UK has granted marketing authorisation to pombiliti (cipaglucosidase alfa) and opfolda (miglustat) for the treatment of adult patients with late-onset pompe disease.
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited launch. The drug is intended to provide new treatment options to patients living with obesity.
Ministers have opened a new vaccine research centre at the UKHSA Porton Down campus in Wiltshire, intended to prepare for 'disease x', the next possible pandemic pathogen.
Bristol Myers Squibb has announced that NICE has recommended Sotyktu (deucravacitinib) for use on the NHS in England as a new treatment option for adult patients with moderate-to-severe plaque psoriasis.
Figures from a team at the University of York, the London School of Economics and Political Science (LSE), and the London School of Hygiene and Tropical Medicine (LSHTM) have revealed that the total cost of prescription medicines to NHS England reached a new high of £17.2bn in 2021-22, and that since 2018, NHS spending on branded medicines have been increasing by over 5% annually.
UK-based trade union Unite were pushing for staff walkouts at several GSK manufacturing sites due to disputes regarding pay increases, however to date there have been no updates as to whether GSK have extended another offer.
NHS England has announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs.
Otsuka Pharmaceuticals has announced that the National Institute for Health and Care Excellence (NICE) has recommended Lupkynis (Voclosporin) in combination with Mycophenolate Mofetil (MMF) as a treatment option for adult patients with active lupus nephritis (LN).
The National Institute for Health and Care Excellence (NICE) has announced that it is recommending two personalised immunotherapy treatments to the Cancer Drugs Fund (CDF) for the treatment of aggressive forms of blood cancers.
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia, following its approval in January 2024.
Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand UNICEF's work to ‘improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India’, according to the press release.
The FDA has granted an expanded orphan drug designation (ODD) for brain cancer immunotherapy survaxm, originally created at Roswell Park Comprehensive Cancer Center.
Merck has announced that the FDA has approved capvaxive (pneumococcal 21-valent conjugate vaccine).
Eli Lilly has announced that the FDA has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for iv infusion) for the treatment of adult patients with early symptomatic Alzheimer’s disease (AD).
AbbVie has announced that the FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adult patients with moderately-to-severely active ulcerative colitis (UC) and moderate to severe crohn’s disease.
Sarepta Therapeutics has announced that the FDA has approved an expansion to the labelled indication for Elevidys (delandistrogene moxapar vovec-rokl) to include individuals with DMD with a confirmed mutation in the DMD gene who are at least four years of age.
Pfizer has announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate-to-severe haemophilia B.
Roche has announced that the FDA has approved its human papillomavirus (HPV) self-collection solution.
Amgen has announced that the FDA has approved Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer who have had disease progression on or after platinum-based chemotherapy.
Eko Health has announced that the FDA has approved its low ejection fraction (low ef) detection artificial intelligence (AI).
AstraZeneca and Daiichi Sankyo have announced that their biologics license application (bla) for datopotamab deruxtecan (dato-dxd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-negative breast cancer who have had prior systemic therapy for unresectable or metastatic disease.
Candel Therapeutics has announced that the FDA has granted orphan drug designation (ODD) to can-2409, Candel’s immunotherapy candidate, for the treatment of pancreatic cancer.
GSK has announced that the FDA has accepted for review a biologics license application (BLA) for its 5-in-1 meningococcal abcwy (menabcwy) vaccine candidate.
Roche has announced that the FDA has approved alecensa (alectinib) for the adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc).
ImmunityBio has announced that the FDA has approved Anktiva (n-803, or nogapendekin alfa inbakicept-pmln) plus bacillus calmette-guérin (bcg) for the treatment of patients with bcg-unresponsive non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), with or without papillary tumours.
AstraZeneca has announced that the EC has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 mutations.
Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction and Embryology (ESHRE) 40th annual meeting, which was held in Amsterdam, the Netherlands.
AbbVie has announced that the EMA's CHMP has granted a positive opinion to Tepkinly (epcoritamab), recommending the conditional marketing authorisation of the drug as a monotherapy treatment for adult patients with relapsed or refractory (r/r) follicular lymphoma (fl).
Janssen, a Johnson & Johnson company, has announced that the CHMP of the EMA has recommended Rybrevant (amivantamab) in combination with chemotherapy.
Pfizer has announced that the EC has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (ciai), hospital-acquired pneumonia (hap), including ventilator-associated pneumonia (vap) and complicated urinary tract infections (cuti), including pyelonephritis.
AstraZeneca has announced that the European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (dato-dxd) in the treatment of two cancers.
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Awiqli (once-daily basal insulin icodec) for the treatment of diabetes in adult patients.
Pfizer has announced that the EC has granted marketing authorisation for Velsipity (etrasimod) in the EU.
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a crispr/cas9 gene-edited therapy.
GSK has announced that the CHMP of the EMA has given a positive recommendation to the company’s momelotinib for patients with myelofibrosis.
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia that is flt3-itd positive.
Roche has announced that the EC has approved the extension of Evrysdi’s marketing authorisation in the EU to include infants under two months with a clinical diagnosis of spinal muscular atrophy (SMA).
GSK has announced that ViiV healthcare has received a positive opinion from the EMA's CHMP, recommending marketing authorisation for cabotegravir long-acting (LA) injectable and tablets for HIV prevention.
The European Parliament has shared its recommendations for a ‘coordinated EU response to health threats posed by antimicrobial resistance,’ according to its press release.
The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The decision was previously expected on 29 March 2023, but has been announced to be “slightly later”.
Pharma giant AstraZeneca has been given a recommendation by the EU's Committee for Medicinal Products (CHMP) for marketing authorisation for ultomiris (ravulizumab), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMSOD) who are anti-aquaporin-4 (AQP4) antibody positive (ab+).
Welcome to the July/August 2024 issue of Pharmafocus!
Welcome to the June 2024 issue of Pharmafocus!
Welcome to the May 2024 issue of Pharmafocus!
Welcome to the April 2024 issue of Pharmafocus!
Welcome to the March 2024 issue of Pharmafocus!
Welcome to the first Pharmafocus of 2024!
With his 20 years of expertise and proven track record in biotech and pharmaceutical industries, Curve Therapeutics appoints Simon Jones as chief financial officer and chief operating officer.
Vectory Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacin Dr Carlo Incerti.
Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.
Professor Yih-Shing Duh appointed as chief scientific advisor by H.E.L. Group
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief executive officer (CEO), following a successful six-month term as interim CEO and COO.
Closed loop medicine has announced the appointment of Paul Johnson as an independent non-executive director.
Sphere Fluidics has announced the appointment of Curtis Nicholson as director for sales for Europe, Middle East and Africa (EMEA).
Drug Safety Research Unit appoints Dr Alison Evans as head of education and training.
Calluna Pharma has announced that it has appointed Margrethe Sørgaard as senior vice president of clinical operations and pharmacovigilance.
Sakura Finetek Europe has announced the appointment of Jaap Stuut as president and general manager, effective immediately.
Harness Therapeutics has announced the appointment of Meenu Chhabra Karson as chair of its board of directors.
Single Technologies has announced that it has appointed Bob Kain as an advisor to support the commercialisation of its 3D sequencing system.
Nuclera has announced that it has appointed Joseph Bertelsen as chief commercial officer (CCO).
BenevolentAI has announced that Dr Daniel Neil, current chief technology officer (CTO) is stepping down, to be succeeded by Dr James Malone, who joins the company in April.
Vynamic has announced the appointment of Gemma Pfister as head of life sciences Europe.
Parexel has announced that its CEO, Jamie MacDonald will retire, with the company’s current chief operating and growth officer Peyton Howell taking over as CEO, effective 15 May 2024.
Pharmaceutical Industry news, analysis and insights